RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $5.29 Consensus Target Price from Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned an average rating of “Hold” from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $5.29.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of RAPT Therapeutics in a research note on Monday, March 10th.

Institutional Trading of RAPT Therapeutics

Several large investors have recently made changes to their positions in RAPT. Trustees of Columbia University in the City of New York purchased a new stake in shares of RAPT Therapeutics in the fourth quarter worth about $116,000. Shay Capital LLC purchased a new stake in RAPT Therapeutics in the 4th quarter worth approximately $81,000. RTW Investments LP acquired a new stake in shares of RAPT Therapeutics during the 4th quarter worth approximately $18,587,000. Redmile Group LLC grew its stake in shares of RAPT Therapeutics by 1,183.4% during the 4th quarter. Redmile Group LLC now owns 6,475,317 shares of the company’s stock worth $10,231,000 after purchasing an additional 5,970,785 shares during the period. Finally, Nuveen Asset Management LLC increased its holdings in shares of RAPT Therapeutics by 50.5% during the 4th quarter. Nuveen Asset Management LLC now owns 116,925 shares of the company’s stock valued at $185,000 after purchasing an additional 39,216 shares in the last quarter. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Price Performance

NASDAQ:RAPT opened at $1.53 on Thursday. The company has a 50-day moving average of $1.17 and a 200 day moving average of $1.47. The firm has a market cap of $201.97 million, a PE ratio of -0.55 and a beta of -0.31. RAPT Therapeutics has a 1-year low of $0.79 and a 1-year high of $9.65.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.69). Sell-side analysts anticipate that RAPT Therapeutics will post -2.14 EPS for the current fiscal year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.